

<p>Substitute for form 1449A/PTO ELEVENTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> </p>		<i>Complete if Known</i>	
		U.S. Application No.	10/042,644
		Filing or 371(c) date	January 8, 2002
		First Named Inventor	Jacques F. BANCHEREAU
		Group Art Unit	1646
		Examiner Name	Gyan Chandra
Sheet 1 of 1		Attorney Docket No: 13786-7	

US PATENT DOCUMENTS			
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
	Bennett et al., "Interferon and granulopoiesis signatures in systemic lupus erythematosus blood", J. Exp. Med., 197:711-723 (2003)	
	KAWADE and WATANABE, "The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies", Immunology 56:489-495 (1985)	
	KONTSEK et al., "Enhancement of neutralizing efficacy by combining three monoclonal antibodies to human interferon-alpha", Immunology, 73:8-11 (1991)	
	Mathian et al., "IFN-alpha induces lethal lupus in young, pre-autoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice", J. Immunol., 174: 2499-2506 (2004)	
	MEAGER, A., "Natural autoantibodies to interferons", J. Interferon Cytokine Res., 17 Suppl. 1:S51-53 (1997)	
	PAQUETTE et al., "Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells", J. Leukocyte Biology 64: 358-367, September 1998.	
	Pascual et al., "The central role of dendritic cells and interferon-alpha in SLE", Curr. Opin. Rheumatol, 15:548-556 (2003)	
	PREBLE et al., "Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon", Science, 216:429-431 (1982)	
	RAANANI et al., "Immune-mediated complications during interferon therapy in hematological patients", Acta Haematol, 107:133-144 (2002)	
	SANTINI et al., "Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in hu-PBL-SCID mice", J. Exp Med 191 (10): 1777-1788, May 15, 2000.	
	SHEARER et al., "Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers", J. Immunol., 133:3096-3101 (1984)	
	WEBER et al. "Single amino acid changes that render human IFN-alpha 2 biologically active on mouse cells", EMBO J., 6:591-198 (1987)	

604293v1

EXAMINER	/Gyan Chandra/	DATE CONSIDERED	11/06/2008
-----------------	----------------	------------------------	------------

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /GC/